High minimum inhibitory concentration of imipenem as a predictor of fatal outcome in patients with carbapenem non-susceptible Klebsiella pneumoniae

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Ping Feng ^a,b   Chuang, Chien ^a   Su, Chin Fang ^a   Lin, Yi Tsung ^a,b   Chan, Yu Jiun ^a,b   Wang, Fu Der ^a,b   Chuang, Yin Ching ^c   Siu, L Kristopher ^d   Fung, Chang Phone ^e  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; IMIPENEM;

ADULT; AGED; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG EFFECT; EPIDEMIOLOGY; FEMALE; GENERAL HOSPITAL; GENETICS; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; FEMALE; HOSPITALS, GENERAL; HOSPITALS, VETERANS; HUMANS; IMIPENEM; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84986265708     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32665     Document Type: Article

References (25)

1. Meatherall, B. L., Gregson, D., Ross, T., Pitout, J. D. & Laupland, K. B. Incidence, risk factors, outcomes of Klebsiella pneumoniae bacteremia. Am J Med 122, 866-873, doi: 10. 1016/j. amjmed. 2009. 03. 034 (2009).
2. Podschun, R. & Ullmann, U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, pathogenicity factors. Clin Microbiol Rev 11, 589-603 (1998).
3. Wu, H. S. et al. Characteristics of healthcare-associated and community-acquired Klebsiella pneumoniae bacteremia in Taiwan. J Infect 64, 162-168, doi: 10. 1016/j. jinf. 2011. 11. 005 (2012).
4. Lin, Y. T., Jeng, Y. Y., Chen, T. L. & Fung, C. P. Bacteremic community-acquired pneumonia due to Klebsiella pneumoniae: clinical and microbiological characteristics in Taiwan, 2001-2008. BMC Infect Dis 10, 307, doi: 10. 1186/1471-2334-10-307 (2010).
5. Lin, Y. T., Liu, C. J., Yeh, Y. C., Chen, T. J. & Fung, C. P. Ampicillin and amoxicillin use and the risk of Klebsiella pneumoniae liver abscess in Taiwan. J Infect Dis 208, 211-217, doi: 10. 1093/infdis/jit157 (2013).
6. Lin, Y. T., Chen, T. L., Siu, L. K., Hsu, S. F. & Fung, C. P. Clinical and microbiological characteristics of community-acquired thoracic empyema or complicated parapneumonic effusion caused by Klebsiella pneumoniae in Taiwan. Eur J Clin Microbiol Infect Dis 29, 1003-1010, doi: 10. 1007/s10096-010-0961-8 (2010).
7. Tzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T. & Daikos, G. L. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25, 682-707, doi: 10. 1128/CMR. 05035-11 (2012).
8. Nordmann, P., Dortet, L. & Poirel, L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 18, 263-272, doi: 10. 1016/j. molmed. 2012. 03. 003 (2012).
9. Daikos, G. L., Markogiannakis, A., Souli, M. & Tzouvelekis, L. S. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev Anti Infect Ther 10, 1393-1404, doi: 10. 1586/eri. 12. 138 (2012).
10. Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E. & Vardakas, K. Z. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20, 1170-1175, doi: 10. 3201/eid2007. 121004 (2014).
11. Orsi, G. B. et al. Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study. Infection 41, 61-67, doi: 10. 1007/s15010-012-0354-2 (2013).
12. CLSI. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S22. Clinical and Laboratory Standards Institute Wayne, PA (2012).
13. van Duin, D. et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother 58, 4035-4041, doi: 10. 1128/AAC. 02636-14 (2014).
14. American Thoracic, S. & Infectious Diseases Society of, A. Guidelines for the management of adults with hospital-acquired, ventilator-associated, healthcare-associated pneumonia. Am J Respir Crit Care Med 171, 388-416, doi: 10. 1164/rccm. 200405-644ST (2005).
15. Horan, T. C., Andrus, M. & Dudeck, M. A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36, 309-332, doi: 10. 1016/j. ajic. 2008. 03. 002 (2008).
16. Lin, Y. T., Wang, F. D., Chan, Y. J., Fu, Y. C. & Fung, C. P. Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniae bacteremia in Taiwan. BMC Infect Dis 14, 1, doi: 10. 1186/1471-2334-14-1 (2014).
17. Lin, Y. T. et al. Efficacy of Appropriate Antimicrobial Therapy on the Survival of Patients With Carbapenem Nonsusceptible Klebsiella Pneumoniae Infection: A Multicenter Study in Taiwan. Medicine (Baltimore) 94, e1405, doi: 10. 1097/MD. 0000000000001405 (2015).
18. Chiu, S. K. et al. National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS One 8, e69428, doi: 10. 1371/journal. pone. 0069428 (2013).
19. Tang, H. J. et al. Identification of the first imported KPC-3 Klebsiella pneumoniae from the USA to Taiwan. Int J Antimicrob Agents 44, 431-435, doi: 10. 1016/j. ijantimicag. 2014. 07. 009 (2014).
20. van Duin, D., Kaye, K. S., Neuner, E. A. & Bonomo, R. A. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 75, 115-120, doi: 10. 1016/j. diagmicrobio. 2012. 11. 009 (2013).
21. Won, S. Y. et al. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 53, 532-540, doi: 10. 1093/cid/cir482 (2011).
22. Patel, T. S. & Nagel, J. L. Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs. J Clin Microbiol 53, 201-205, doi: 10. 1128/JCM. 03057-14 (2015).
23. Biehle, L. R. et al. Outcomes and Risk Factors for Mortality among Patients Treated with Carbapenems for Klebsiella spp. Bacteremia. PLoS One 10, e0143845, doi: 10. 1371/journal. pone. 0143845 (2015).
24. Esterly, J. S. et al. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother 56, 4885-4890, doi: 10. 1128/AAC. 06365-11 (2012).
25. Shields, R. K. et al. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. Antimicrob Agents Chemother 59, 1797-1801, doi: 10. 1128/AAC. 03894-14 (2015).